Global Nocturnal Leg Cramps Treatment Market, By Drug Class (Calcium Channel Blockers, Nonsteroidal Anti-Inflammatory (NSAID), Others), Route of Administration (Oral, Topical, Others), Dosage Form (Tablets, Ointments, Gels, Others), Diagnosis (Physical Examination, Blood Tests, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Nocturnal leg cramps affect up to 60% of adults. Recurrent, painful tightness of the calf muscles is common and can cause severe sleeplessness. The specific mechanism is uncertain, but muscle exhaustion and nerve malfunction are more likely to induce cramps than electrolyte or other disorders. Vascular disease, lumbar canal stenosis, cirrhosis, hemodialysis, pregnancy, and other medical disorders are all linked to nocturnal leg cramps. Intravenous iron sucrose, conjugated estrogens, raloxifene, naproxen, and teriparatide are all medications that are closely linked to leg cramps. A history and physical examination are typically sufficient to distinguish nocturnal leg cramps from other disorders such as restless legs syndrome, claudication, myositis, and peripheral neuropathy.
Data Bridge Market Research analyses that the nocturnal leg cramps treatment market was valued at USD 364 million in 2021 and is expected to reach USD 658.91 million by 2029, registering a CAGR of 7.70% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Leg cramps that occur at night are characterized by a tight, knotted sensation in the legs. Painful as well as involuntary spasms in the calf or thighs arise during the night. Lack of physical activity, extended standing, or tendon shortening are the most common causes. They can last anything from a few seconds to a few minutes. Your muscle may be sore for days if the cramp is severe.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Calcium Channel Blockers, Nonsteroidal Anti-Inflammatory (NSAID), Others), Route of Administration (Oral, Topical, Others), Dosage Form (Tablets, Ointments, Gels, Others), Diagnosis (Physical Examination, Blood Tests, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (UK), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (US), Bayer AG (Germany), Perrigo Company plc (Ireland), Tolmar Pharmaceuticals, Inc. (US), Reckitt Benckiser Group PLC (UK), Sun Pharmaceutical Industries Ltd. (India), Assertio Therapeutics, Inc. (US), DAIICHI SANKYO COMPANY, LIMITED (Japan)
|
|
Market Opportunities
|
|
Nocturnal Leg Cramps Treatment Market Dynamics
Drivers
- Increasing prevalence of nocturnal leg cramps
The rising prevalence of nocturnal leg cramps is estimated to enhance the nocturnal leg cramps treatment market's growth. Leg cramps throughout the night are reported by 50 to 60 percent of adults and about 7% of youngsters. Women are slightly more likely to have them, and their prevalence rises with age.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of nocturnal leg cramps treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Growing number of geriatric population
The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get nocturnal leg cramps treatment, further estimated to enhance the market's growth rate.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the nocturnal leg cramps treatment market. Additionally, rise in focuses on management of the nocturnal leg cramps and sedentary lifestyle of people will result in the expansion of nocturnal leg cramps treatment market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the nocturnal leg cramps treatment market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the nocturnal leg cramps treatment market growth during the forecast period.
Restraints/Challenges
On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. Limited primary care services and lack of healthcare infrastructure in developing economies will challenge the nocturnal leg cramps treatment market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.
This nocturnal leg cramps treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the nocturnal leg cramps treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Nocturnal leg are found in 40% of people over the age of 50 in the general population, grow in frequency with age, have no sex preference, and are linked to sleep disturbances and ill health. Around 7% of children and adolescents have experienced nocturnal leg cramps. The peak age of occurrence in this cohort was 16 to 18 years old, with no instances reported in children under eight. In most cases, nocturnal leg cramps in children are harmless, self-limiting, and uncommon.
Nocturnal leg cramps treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Nocturnal Leg Cramps Treatment Market
Over the projected period, the nocturnal leg cramps treatment market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The nocturnal leg cramps treatment market was hampered by the supply chain slowness.
Global Nocturnal Leg Cramps Treatment Market Scope
The nocturnal leg cramps treatment market is segmented on the basis of drug class, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Calcium Channel Blockers
- Nonsteroidal Anti-Inflammatory (NSAID)
- Others
Diagnosis
- Physical Examination
- Blood Tests
- Others
Dosage Form
- Tablets
- Ointments
- Gels
- Others
Route of Administration
- Oral
- Topical
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Nocturnal Leg Cramps Treatment Market Regional Analysis/Insights
The nocturnal leg cramps treatment market is analysed and market size insights and trends are provided by country, drug class, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the nocturnal leg cramps treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the nocturnal leg cramps treatment market because of the growing prevalence of sedentary lifestyles in this region. Additionally, rising healthcare expenditure along with the availability of treatment options will further propel the market's growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to presence of major generic pharmaceuticals companies in this region. Also, the development of healthcare infrastructure will further propel themarket's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Nocturnal Leg Cramps Treatment Market Share Analysis
The Nocturnal leg cramps treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to nocturnal leg cramps treatment market.
Some of the major players operating in the nocturnal leg cramps treatment market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France), Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Zydus Cadila (India)
- Boehringer Ingelheim International GmbH. (Germany)
- Apotex Inc. (Canada)
- AstraZeneca (UK)
- Horizon Therapeutics PLC (Ireland)
- Johnson & Johnson (US)
- Bayer AG (Germany)
- Perrigo Company plc (Ireland)
- Tolmar Pharmaceuticals, Inc. (US)
- Reckitt Benckiser Group PLC (UK)
- Sun Pharmaceutical Industries Ltd. (India)
- Assertio Therapeutics, Inc. (US)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
SKU-